| Autor: |
Restrepo S; Corporación de Investigaciones Biológicas (CIB), Hospital Pablo Tobón Uribe, Medellin, Colombia., Tabares AM, Restrepo A |
| Jazyk: |
angličtina |
| Zdroj: |
Revista do Instituto de Medicina Tropical de Sao Paulo [Rev Inst Med Trop Sao Paulo] 1992 Mar-Apr; Vol. 34 (2), pp. 171-6. |
| DOI: |
10.1590/s0036-46651992000200014 |
| Abstrakt: |
A new orally absorbable triazole (Schering 39304) with a long serum half-life in man (60 hours), was tried in a murine model of progressive paracoccidioidomycosis and compared with itraconazole, another triazole which has proven effective in this mycosis. Only 15% of the infected, untreated mice survived while 53 to 75% of the animals receiving itraconazole survived. Mice treated with Schering 39304 exhibited higher (86-100%) survival rates. Statistically, the 5 mg/kg Sch 39304 was superior to the 50 mg/kg itraconazole dose. Lung cultures showed that 20 mg/kg/day of Sch achieved sterilization of the infectious foci. These results indicate that the new triazole will have a place in the treatment of paracoccidioidomycosis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
